

## **EXHIBIT 8**

**Exhibit 8: Pechiney's Objections to Cryovac's Deposition Designations**

<b>KELLY RAY AHLGREN</b> <b>8/10/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
48:11, 12, 14, 15	FRE 602, FRE 701, FRE 802
72:18-73:4	FRE 701, FRE 802
74:7-16	FRE 701, FRE 802
80:14-81:2, 81:10-82:7	FRE 602, FRE 701, FRE 802
101:21-103:1	FRE 602, FRE 701, FRE 802
107:16, 17, 107:20-108:3	FRE 602, FRE 701
158:18-20, 158:22-159:6	FRE 602, FRE 701
229:11-232:2	FRE 403, FRE 602, FRE 701

DUANE BEULOW 7/27/2005	
Cryovac's Designations	Pechiney's Objections
60:20-22; 61:20-62:2	FRE 602
83:2; 83:5-9	FRE 602
112:7-8; 112:11-15; 112:17-113:3	FRE 602, FRE 701
124:22-125:3; 125:6-7	FRE 602, FRE 802
127:17-20; 128:5-13; 141:3-142:2; 142:15-143:9; 143:21-144:16; 145:12-22; 146:8-10; 146:12-14; 146:19-147:21; 148:1-9; 149:11-16; 150:3-6; 151:8-9; 152:3-6; 153:1-13; 153:20-154:5; 154:10-17; 156:21-157:5; 158:4-7	FRE 602, FRE 802
164:10-16; 165:18-166:11	FRE 602, FRE 802

<b>RICHARD COMPANY</b>	
<b>8/23/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
44:22-45:7	FRE 602
52:2-53:8	FRE 602, FRE 802

MICHAEL DOUGLAS 8/3/2005	
Cryovac's Designations	Pechiney's Objections
141:5-10	FRE 403
142:22-143:4, 144:14-145:1, 145:16-146:8	FRE 403, FRE 602, FRE 802
148:19-21, 151:4-7, 154:8-19, 160:9-16, 160:21-162:6, 162:13-16	FRE 403, FRE 602, FRE 802
191:12-21	FRE 602
210:17-19, 211:62-11, 212:15- 213:8, 214:11-215:14	FRE 402, FRE 403, FRE 602, FRE 802

<b>MICHAEL DOUGLAS - 30(B)(6)</b> <b>8/3/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
	N/A

ENNIS M. FANT 7/19/2005	
Cryovac's Designations	Pechiney's Objections
23:18-20; 24:1	FRE 602, FRE 701
44:22-45:15	FRE 402, FRE 403, FRE 602
46:10-13	FRE 402, FRE 403, FRE 602
54:21-55:9	FRE 402, FRE 403
132:11-133:1; 133:3; 133:5-8	FRE 402, FRE 403
133:10-14	FRE 402, FRE 403
133:15-16; 133:18	FRE 402, FRE 403, FRE 701

STEVEN L. FULLER 8/18/2005	
Cryovac's Designations	Pechiney's Objections
111:25-112:5; 113:4-12; 113:24-114:6; 114:16-115:4	FRE 403, FRE 602, FRE 701



STEVEN B. GARLAND 8/9/2005	
Cryovac's Designations	Pechiney's Objections
43:6-9; 44:8-10; 83:1-4; 83:6-7	FRE 602, FRE 701, FRE 802

THOMAS GRABOWSKI 7/29/05	
Cryovac's Designations	Pechiney's Objections
61:21-62:5	FRE 802
74:16-76:2	FRE 402, FRE 602, FRE 701, FRE 802
77:13-78:2	FRE 403, FRE 602, FRE 701
85:8-87:19	FRE 602, FRE 701
99:17-100:14	FRE 602
105:14-106:7	FRE 802
119:21-120:4	FRE 602
123:3-124:7	FRE 602, FRE 802
126:10-19	FRE 802
167:22-170:11	FRE 602
178:11-180:1	FRE 802
187:11-188:18	FRE 403, FRE 602, FRE 802
197:1-10	FRE 602
218:3-219:5	FRE 802
236:13-238:4	FRE 602, FRE 701
252:19-253:14	FRE 602
255:21-257:9	FRE 602

<b>STEVEN JAMES</b> <b>9/7/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
	N/A

<b>TOMMY KAY</b> <b>8/16/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
	N/A

<b>FRANK KITCHEL</b> <b>7/28/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
86:9-87:2	FRE 402, FRE 403, FRE 602
87:11-17	FRE 402, FRE 403, FRE 602
88:6-89:9	FRE 402, FRE 403, FRE 602
95:22 - 96:12	FRE 402, FRE 403, FRE 602

<b>CHAD MUELLER</b> <b>7/7-8/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
203:4-17	FRE 602, FRE 802
204:5-204:10	FRE 602, FRE 802
272:4-11, 293:1-4	FRE 402, FRE 403, FRE 602

<b>GAUTAM P. SHAH</b>	
<b>8/11/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
60:16-19; 61:1-3	FRE 403, FRE 701
118:20-119:8	FRE 602, FRE 701

GAUTAM P. SHAH – 30(B)(6) 8/11/2005	
Cryovac's Designations	Pechiney's Objections
9:17-21	FRE 403, FRE 701
17:17-18:10	FRE 403, FRE 701
31:3-5; 31:20-32:1	FRE 403, FRE 701
34:9-12; 34:21-22; 35:3-4	FRE 403, FRE 701
36:7-9; 36:12-17; 36:19-20	FRE 403, FRE 701
37:16-18; 37:21-38:1	FRE 403, FRE 701
38:6-15	FRE 403, FRE 701



<b>F. DAVID STRINGER</b> <b>8/19/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
	N/A

<b>ROBERT TAYLOR</b> <b>7/14/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
	N/A

<b>ROBERT TAYLOR – 30(B)(6)</b> <b>11/10/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
27:16-28:7	FRE 402
33:4-9	FRE 402
33:11-36:6	FRE 701
47:18-49:21	FRE 602, FRE 701
52:10-16	FRE 402
78:17-79:7	FRE 602
88:10-89:5	FRE 402
99:13-100:5	FRE 602
111:4-116:10	FRE 602, FRE 701
142:10-19	FRE 602, FRE 701
156:12-157:7	FRE 602

TERRY L. WILKERSON 8/24/2005	
Cryovac's Designations	Pechiney's Objections
207:8-209:4	FRE 402, FRE 403, FRE 602, FRE 802

<b>GEORGE WOFFORD</b> <b>8/12/2005</b>	
<b>Cryovac's Designations</b>	<b>Pechiney's Objections</b>
81:14-20, 82:1-7	FRE 403, FRE 602, FRE 701
84:21-85:13, 86:7-88:1	FRE 403, FRE 602
99:17-19, 99:22-100:4, 100:6-8, 100:11-22	FRE 403, FRE 602
145:1-2, 145:5-10	FRE 602
162:13-18, 163:1-8	FRE 403, FRE 602, FRE 802
208:2-16	FRE 403, FRE 602, FRE 802
235:1-4	FRE 403, FRE 602

## **EXHIBIT 9**

**Exhibit 9: Pechiney's Deposition Designations and Crvovac's Counter-Designations**

<b>Kelley Ray Ahlgren</b>  8/10/2005	Pechiney Designations	6:9-12; 6:17-19; 8:21-9:11; 10:7-15; 10:22-11:6; 11:11-12:7; 23:15-17; 24:12-21; 26:20-27:6; 28:17-29:14; 31:21-32:6; 61:14-62:5; 66:20-67:17; 87:8-88:20; 109:6-20; 131:6-20; 162:22-163:6; 178:22-181:13; 185:6-186:10; 199:4-9; 200:15-201:14
	Cryovac Counter- Designations	31:9-20; 32:8-10; 32:18-20; 48:11-12; 48:14-15; 55:2-8; 55:22-56:11; 57:20-58:3; 58:5-7; 67:20-68:2; 68:18-22; 69:5-13; 72:18-73:4; 74:7-16; 77:4-10; 77:13-78:3; 78:6-15; 78:20-79:1; 79:3-4; 79:6-14; 80:14-81:1; 81:10-82:7; 82:14-84:6; 85:4-5; 85:7; 85:9-15; 101:21-103:1; 107:16-17; 107:20-108:3; 159:18-20; 159:22-160:6; 181:15-182:1; 182:4-7; 199:10-11; 199:13-17; 203:2-8; 223:10-12; 223:14-20; 224:3-14; 229:11-232:2.
<b>Karl Deily</b>  8/19/2005	Pechiney Designations	10:9-11:22; 33:2-17; 36:13-50:22; 51:3-52:12; 72:5-74:19; 78:17-82:20; 86:20-90:1; 90:3-93:21; 94:13-98:19; 100:3-104:9; 104:11-106:18; 116:7-119:6; 127:4-128:10; 138:16-139:5; 143:3-147:3; 148:4-151:11; 158:8-160:19; 165:5-169:9; 170:8-16; 172:5-177:13; 182:7-184:5; 185:11-186:21; 225:21-227:11; 232:10-240:13; 244:10-263:12; 260:8-263:12; 284:2-294:2; 294:6-298:17; 298:19-20; 301:4-304:3; 304:13-305:14; 305:20-307:13
	Cryovac Counter- Designations	34:13-36:2; 36:4-11*; 52:13-15*; 52:17-21*; 77:8-10*; 77:12-16*; 77:20-78:1*; 78:4-8*; 78:10-15*; 82:21-83:1; 83:4-8*; 83:10-11*; 83:14-17*; 84:17-19*; 84:22-85:7*; 85:10-86:8*; 86:11-14*; 119:7-8; 137:9-13; 137:17-138:15; 142:5-10; 142:17-143:1; 152:4-16; 170:20-171:12; 181:5-8; 181:18-182:6; 188:3-13; 195:22-196:4; 196:14-17; 197:2-8; 197:13-198:5; 200:15-201:12; 201:16-20; 227:12-230:3; 230:6-231:5; 231:7; 231:17-232:3; 241:3-22; 242:4-7; 242:9-11; 242:13-243:4; 243:6-9; 243:11-21; 282:13-20

\*Cryovac only counter-designates this testimony if its objections to Pechiney's designations are overruled.

<b>Ennis M. Fant</b>  7/19/2005	Pechiney Designations	6:11-14; 7:6-9; 8:22-9:-17; 10:3-7; 20:3-23:17; 24:19-29:18; 31:16-32:4; 33:7-34:16; 34:20-36:7; 42:9-19; 45:16-46:9; 46:14-47:3; 50:9-19; 55:10-56:9; 57:9-62:2; 67:1-10; 67:18-68:2; 75:7-76:6; 78:4-79:1; 83:2-84:11; 89:22-92:5; 93:5-94:12; 95:17-96:3; 100:7-102:7; 102:18-105:20; 109:7-18; 113:8-114:3; 119:6-120:10; 124:22-125:21; 127:12-14; 127:20-129:12
	Cryovac Counter-Designations	30:6-12; 30:18-31:8; 31:10-15; 36:15-22; 39:19-22; 44:22-45:15; 46:10-13; 47:7-48:14; 54:21-55:9; 68:3-6; 68:9-69:4; 105:21-106:15; 132:11-133:1; 133:3; 133:5-8; 133:10-16; 133:18; 133:22-135:5
<b>Steven L. Fuller</b>  8/18/2005	Pechiney Designations	4:10-5:22; 6:15-18; 23:3-5; 28:19-21; 33:15-18; 35:12-36:24; 39:16-41:3; 80:17-93:10
	Cryovac Counter-Designations	47:14-19; 111:25-112:5; 113:4-12; 113:24-114:6; 114:16-115:4
<b>Jeffrey Gardner</b>  8/2/2005	Pechiney Designations	8:14-17; 12:5-17; 11:12-12:17; 15:10-16:2; 16:15-21; 20:3-21:6; 22:17-23:17; 24:16-26:19; 28:5-33:19; 34:3-36:4; 37:11-38:14; 38:21-39:13; 40:4-41:5; 41:11-42:22; 43:20-58:14; 60:14-21; 62:2-63:18; 63:22-64:16; 87:14-88:12; 90:2-16; 95:2-96:22; 97:6-102:10; 134:18-144:5; 171:12-173:19; 177:13-183:17; 184:15-194:9; 200:2-204:1; 209:6-212:11; 212:12-215:10; 215:11-220:5; 220:11-221:21; 226:14-227:6; 257:11-259:11
	Cryovac Counter-Designations	13:11-14:1; 14:11-15; 16:3-14; 18:1-7; 18:14-15; 21:7-22:14; 23:18-24:15; 27:3-9; 27:16-28:3; 36:12-16; 39:14-40:3; 41:6-10; 43:1-4; 43:6-7; 58:15-59:13; 59:19-60:4; 71:2-6; 88:13-90:1; 90:21-91:6; 92:1-12; 94:1-7; 94:14-95:1; 97:1-5; 102:11-103:7*; 103:15-20; 103:22-104:21; 106:11-16; 106:21-109:15; 116:6-12; 133:1-134:9; 151:1-4; 156:2-5; 194:10-195:4*; 195:6-198:10*; 198:12-202:1*; 220:6-10*; 221:22-222:12*

\*Cryovac only counter-designates this testimony if its objections to Pechiney's designations are overruled.



<b>Stephen B. Garland</b>  8/9/2005	Pechiney Designations	8:10-14; 8:18-22; 12:21-13:21; 18:3-5; 18:15-19:1; 19:10-12; 25:13-16; 26:8-27:18; 38:21-42:3; 44:13-45:10; 52:8-16; 53:6-20; 79:1-79:16; 98:3-100:16; 101:18-102:15; 110:11-115:10; 128:16-133:21; 136:4-137:5; 149:20-152:12; 155:1-21; 156:19-157:4; 160:12-162:18; 163:19-168:15; 169:11-15
	Cryovac Counter-Designations	10:22-11:4; 43:6-9; 44:8-10; 83:1-4; 83:6-7
<b>Steve James</b>  9/7/2005	Pechiney Designations	5:12-15; 7:22-8:6; 8:16-10:6; 11:6-12:24; 13:21-18:5; 21:1-22:13; 25:6-22; 26:13-29:19; 30:5-15; 31:1-32:1; 32:9-21; 35:22-36:22; 40:12-41:14; 48:20-49:20; 50:4-51:25
	Cryovac Counter-Designations	7:20-21; 18:17-22; 19:14-20:23; 29:20-21*; 30:2-4*; 33:8-15; 33:22-25; 34:8-35:8; 37:9-14; 37:19-38:2; 38:18-23; 39:4-5; 39:8-40:11; 41:15-47:4; 47:8-24; 53:2-10
<b>Tommy Kay</b>  8/16/2005	Pechiney Designations	3:22-23; 4:1-5; 8:20-22; 12:18-19; 18:12-16; 19:11-20:5; 22:16-23:14; 23:25-24:18; 24:23-25:12; 26:4-30:10; 33:24-35:3; 35:15-39:16; 40:12-42:2; 42:10-45:15; 46:19-47:8; 48:10-51:12; 54:3-55:16; 58:1-59:9; 60:24-62:15; 63:25-67:24; 68:16-76:9; 76:23-85:9; 90:1-8; 95:24-96:6; 103:21-105:1; 105:24-106:3; 110:13-111:2; 112:2-114:15; 115:9-12; 115:16-116:16; 116:20-122:12; 122:22-124:2; 125:4-22; 126:9-127:9; 128:4-129:17; 135:21-136:4; 136:20-140:5; 140:13-145:10; 146:2-147:3; 148:13-152:1; 153:14-18; 157:8-13; 158:13-159:2; 161:14-162:1; 163:8-10; 167:6-171:10; 173:7-174:4; 174:18-176:15; 176:23-177:5; 189:2-195:5; 198:21-25; 201:11-14; 201:22-202:14
	Cryovac Counter-Designations	6:3-11; 6:23-7:13; 8:23-25; 9:3-16; 10:3-11; 12:20-14:9; 14:17-15:3; 16:3-9; 16:15-17:2; 39:17-22; 39:24-40:11; 46:11-15; 52:12-53:5; 55:17-56:7; 68:5-15; 92:13-15; 127:10-19; 129:18-24; 172:11-21; 195:21-196:25; 203:13-25; 204:4-7

\*Cryovac only counter-designates this testimony if its objections to Pechiney's designations are overruled.

<b>Robert M. Kimmel</b>  7/13/2005	Pechiney Designations	7:4-13; 10:11-11:6; 11:19-12:6; 25:3-14; 33:12-22; 51:22-54:12; 55:12-57:18; 60:18-21; 61:14-63:17; 72:8-74:1; 74:21-75:14; 79:13-14; 81:8-20; 101:1-20; 103:19-104:1; 104:10-15; 104:22-105:5; 146:14-147:4; 154:1-7; 161:6-22; 198:16-199:1; 217:2-11; 218:9-219:7; 229:9-230:18; 231:4-9; 231:22-232:5; 256:19-257:12; 258:8-12; 261:3-263:4; 265:7-22; 266:17-267:3; 267:14-268:5; 269:19-274:8
	Cryovac Counter-Designations	25:17-22; 26:17-27:17; 29:6-13; 29:20-30:7; 32:10-33:11; 34:3-9; 34:16-20; 35:1-11; 59:9-60:4; 64:4-20; 65:18-66:19; 71:18-72:7; 75:15-22; 76:14-77:11; 78:9-79:7; 104:2-9; 105:6-21; 150:8-153:22; 157:1-161:5; 197:7-12; 197:18-198:15; 233:18-234:21; 235:7-15; 236:11-237:8; 266:510; 274:13-21; 275:8-16
<b>James Mize</b>  8/17/2005	Pechiney Designations	9:10-14; 17:15-19:12; 29:22-30:13; 61:22-69:22; 74:17-75:18; 93:17-100:5; 100:13-112:1; 137:22-141:18; 153:22-166:7; 169:3-178:20; 179:1-185:13; 189:18-211:21; 212:6-213:4; 213:19-223:16; 223:22-228:2; 230:10-11; 231:11-14; 232:20-234:14; 234:22-236:12; 238:13-243:6; 250:5-22
	Cryovac Counter-Designations	33:12-19; 33:22-34:1; 35:8-14; 72:14-22; 73:4-5; 73:9-74:2; 74:4-9; 78:10-79:16; 80:22-81:12; 86:18-87:11; 248:11-249:17
<b>Stuart Prosser</b>  9/14/2005	Pechiney Designations	6:8-10; 10:19-11:7; 12:1-15:6; 18:8-20:10; 22:9-23:24; 28:17-30:24; 32:7-35:15; 38:13-40:7; 41:1-44:19; 46:4-48:2
	Cryovac Counter-Designations	21:1-21; 25:9-12; 31:1-14; 31:21-32:2; 37:3-38:3; 50:1-51:3

\*Cryovac only counter-designates this testimony if its objections to Pechiney's designations are overruled.

<b>Mark Quatt</b>  8/12/2005	Pechiney Designations	6:7-7:13; 10:13-11:20; 12:2-18; 14:2-15:4; 15:8-16; 15:18-16:6; 17:18-18:2; 18:11-16; 20:18-21:2; 22:3-18; 23:5-9; 23:21-24:4; 25:17-26:7; 26:17-27:8; 33:19-34:5; 38:19-39:16; 39:21-40:20; 43:14-44:7; 45:16-46:22; 47:1- 5; 49:17-51:3; 51:13-52:21; 54:6-11; 55:10-56:14; 57:10- 18; 60:6-61:1; 61:9-16; 67:12-68:8; 69:21-70:5; 70:11- 71:2; 71:12-22; 72:9-74:16; 74:21-75:4; 79:15-80:7; 80:18-85:6; 85:21-86:3; 87:11-89:5; 90:17-93:9; 94:2-6; 97:22-98:8; 105:7-108:6; 115:17-22; 116:4-117:16; 124:10-16; 126:2-127:16; 128:14-129:8; 130:14-22; 134:9-135:16; 136:7-11; 138:8-142:13; 142:21-143:13; 144:3-14; 147:16-148:12; 150:11-151:4; 159:15-160:6; 163:15-164:16; 171:14-174:7; 174:11-175:13; 176:17- 177:11; 202:7-12; 203:6-15; 204:12-15; 206:11-207:5; 208:3-17; 210:10-219:14; 220:20-223:15; 228:1-13; 235:20-236:10; 236:15-19
	Cryovac Counter- Designations	8:6-14; 11:21-12:1; 21:7-12; 22:19-23:4; 23:12-20; 41:5- 42:4; 61:17-62:8; 68:9-69:3; 72:1-8; 119:7-120:11; 135:17-19; 144:15-145:8; 148:13-149:2; 155:17-157:7; 165:14-18; 165:21-166:22; 169:19-171:3; 229:17-230:4; 230:11-15

\*Cryovac only counter-designates this testimony if its objections to Pechiney's designations are overruled.

<b>Gautam P. Shah</b>  8/11/2005	Pechiney Designations	8:10-17; 12:2-4; 13:10-15; 14:6-9; 14:18-16:20; 17:8-19:15; 27:2-28:5; 32:9-32:22; 33:12-35:3; 35:15-36:7; 41:1-45:3; 48:16-49:2; 50:21-51:22; 59:2-16; 63:5-64:4; 64:17-65:4; 65:10-67:8; 67:20-68:8; 70:2-71:19; 74:2-75:15; 79:4-82:12; 83:1-84:21; 85:5-91:1; 91:17-93:1; 94:13-95:1; 96:7-22; 99:18-22; 100:11-111:10; 104:10-105:5; 105:20-118:19; 121:14-123:5; 128:4-20; 129:16-130:22; 131:12-132:21; 133:15-135:10; 135:15-18; 136:22-138:9; 138:22-143:5; 143:8-11; 144:15-146:7; 149:10-151:15; 152:7-152:10; 154:19-156:14; 157:1-160:9; 166:4-167:6; 167:18-168:4; 168:16-169:20; 170:20-171:21; 172:3-8; 173:2-11; 175:22-177:13; 178:13-179:11; 179:21-180:16; 192:4-193:8; 194:2-199:2; 201:3-14; 206:21-213:1; 213:15-214:5; 214:15-215:19; 216:21-217:18; 223:1-9; 226:7-230:12; 234:11-15; 235:1-236:17; 237:5-241:16; 243:17-244:5; 245:15-253:7; 254:4-255:14; 258:10-259:11
	Cryovac Counter-Designations	11:14-12:21; 13:16-14:5; 35:5-8; 35:10-13; 36:8-18; 47:21-48:15; 55:17-19; 55:21-56:4; 59:18-20; 59:22-60:6; 60:16-19; 61:1-6; 61:8-15; 64:5-16; 73:2-19; 73:21-22; 95:3-8; 95:20-96:6; 100:1-4; 118:20-119:8; 123:6-11; 127:17-19; 127:21-128:2; 128:22-129:1; 129:3-4; 146:8-9; 146:21-148:3; 148:5-20; 148:22-149:8; 169:22-170:2; 170:4-6; 178:3-4; 178:6-8; 180:17-181:4; 181:6-14
<b>Gautam P. Shah</b>  30(B)(6)  8/11/2005	Pechiney Designations	6:16-22; 7:15-8:5; 8:22-9:5; 12:7-21; 15:1-9; 20:4-28:8; 29:6-9; 29:17-31:1; 32:18-33:2; 39:6-40:15; 49:15-50:2
	Cryovac Counter-Designations	6:9-13; 9:17-21; 10:19-21; 11:3-10; 15:10-12; 15:16-16:4; 16:16-18:10; 19:21-20:3; 31:3-5; 31:20-32:1; 34:9-12; 34:21-22; 35:3-4; 36:7-9; 36:12-17; 36:19-20; 37:16-18; 37:21-38:1; 38:6-15; 40:21-41:5

\*Cryovac only counter-designates this testimony if its objections to Pechiney's designations are overruled.

<b>F. David Stringer</b>  8/19/2005	Pechiney Designations	3:21-22; 4:13-18; 19:25-20:9; 54:4-55:22; 63:20-25; 71:22-73:24; 75:6-76:8; 77:17-89:5; 91:25-92:14; 94:23- 96:4; 97:6-98:13; 99:23-25; 100:20-118:9; 123:2-125:23; 145:17-146:8
	Cryovac Counter- Designations	5:1-8; 5:17-20; 6:22-7:2; 55:23-56:5; 118:10-14; 118:17- 20; 125:24-126:6; 126:9-129:25; 144:6-11
<b>Terry Wilkerson</b>  8/24/2005	Pechiney Designations	10:5-19; 12:2-19:24; 20:5-23:3; 23:13-25; 24:24-37:11; 37:15-39:4; 39:10-40:3; 40:19-41:18; 42:5-43:16; 46:21- 47:18; 50:20-51:11; 51:12-25; 56:11-57:24; 58:3-11; 58:20-59:15; 61:22-63:23; 71:6-14; 73:7-75:4; 76:11- 77:24; 77:25-81:6; 87:1-88:2; 88:3-89:8; 90:12-94:19; 95:1-96:1; 96:8-99:4; 102:8-104:17; 106:16-107:15; 113:24-114:14; 114:25-116:1; 118:7-127:8; 129:15- 130:13; 137:23-139:15; 141:3-142:12; 143:2-23; 145:4- 21; 154:5-155:21; 156:2-14; 156:21-157:22; 159:4-21; 168:17-169:1; 169:12-16; 173:19-22; 175:20-25; 179:16- 19; 180:5-9; 181:20-182:1; 182:24-183:7; 184:11-22; 186:12-187:11; 188:10-189:4; 189:7-19; 198:2-18; 199:5- 9; 225:10-20; 226:14-228:13; 229:24-232:1; 232:9-20
	Cryovac Counter- Designations	19:25-20:4; 24:1-3; 40:13-18; 52:1-7; 57:25-58:2; 107:23- 24; 108:4-111:16; 112:1-113:20; 114:15-24; 116:2-118:6; 127:17-128:9; 129:2-14; 130:14-17; 131:12-132:21; 133:11-12; 134:1-2; 134:6-136:3; 136:18-21; 137:2-22; 142:13-16; 143:24-144:19; 144:24-25; 145:3; 145:9-13; 145:24-148:11; 148:14-151:10; 151:15-24; 152:1-153:3; 155:22-156:1; 156:15-20; 157:23-25; 158:10-12; 158:22- 159:3; 159:22-160:20; 161:17-25; 170:14-171:13; 171:24- 173:1; 174:15-19; 175:11-19; 182:2-23; 183:8-184:10; 189:20-23; 190:3-4; 199:10-25; 202:22-203:12; 206:4-12; 206:22-207:7; 212:1-213:13; 213:21-215:13; 216:6-18; 218:3-219:12; 219:16-17; 219:20-220:10; 221:13-222:17; 223:9-17; 226:3-6; 232:21-233:1

\*Cryovac only counter-designates this testimony if its objections to Pechiney's designations are overruled.

<b>Garth L. Wilkes</b>  7/20/2005	Pechiney Designations	7:10-17; 28:14-29:11; 37:4-38:22; 60:13-20; 69:14-70:4; 101:17-102:13; 107:21-108:7; 120:7-121:14; 156:21-157:15; 165:19-20; 166:2-167:10; 169:16-176:14; 186:3-190:21; 200:1-203:21; 220:4-222:18; 233:11-234:20; 235:4-16; 236:7-13; 237:8-238:10; 239:5-12; 240:5-15; 252:5-21; 256:21-258:15; 259:6-19; 263:21-264:5; 266:6-267:21; 269:11-270:15; 274:22-276:13; 319:4-320:14; 326:19-327:11; 328:8-329:10; 329:21-330:6; 331:2-5; 332:4-333:11
	Cryovac Counter-Designations	15:2-6; 16:14-17:2; 29:12-21; 39:1-8; 60:21-61:22; 62:15-64:11; 66:15-68:2; 70:5-19; 99:15-100:15; 100:19-101:6; 101:9-12; 102:18-103:9; 106:12-107:4; 107:6-19; 109:11-111:15; 167:11-168:11; 168:13-169:15; 190:22-191:9; 191:11-192:8; 204:12-14; 204:16-205:13; 205:16-206:3; 206:5-206:14; 206:16-207:3; 229:14-230:16; 232:18-233:6; 239:14-240:4; 240:17-22; 241:2-242:9; 242:11-243:7; 252:22-253:3; 253:16-20; 254:11-255:10; 255:12-256:20; 259:20-260:8; 264:6-9; 292:13-293:6; 294:4-295:4; 297:7-11; 297:14-298:3; 298:5-13; 300:20-301:15; 301:17-302:3; 307:17-309:4; 311:7-9; 311:11-312:21; 316:18-317:3; 321:22-322:10; 329:11-20; 331:6-12; 333:12-14; 334:2-8; 334:11-337:20; 337:22-338:12; 338:20-340:4; 340:6-9
<b>Jay Wilson</b>  11/3/2005	Pechiney Designations	4:12-17; 12:22-13:13; 15:3-17:10; 18:13-25:17; 31:11-39:19; 43:9-22; 50:5-52:17; 67:9-21; 69:9-70:5; 73:19-78:8; 83:5-84:13; 86:2-87:16; 88:13-93:14; 98:5-103:1; 103:21-104:5; 105:7-107:21; 108:8-110:13; 113:10-114:6
	Cryovac Counter-Designations	12:7-8; 12:13-21; 39:20-41:8*; 42:12-14; 42:16-43:8; 53:6-20*; 53:22-54:2*; 54:4-55:4*; 55:6*; 55:8-10*; 55:12*; 55:14-19*; 55:21-56:2*; 56:4-12*; 56:14-15*; 56:17-59:16*; 60:12-61:1*; 62:17-63:3*; 66:22-67:2; 67:5-7; 67:22-68:14*; 70:6-19; 84:19-85:4*; 85:11-86:1; 97:7-98:4*

\*Cryovac only counter-designates this testimony if its objections to Pechiney's designations are overruled.

<b>George Wofford</b>  8/12/2005	<b>Pechiney Designations</b>	8:6-10; 8:16-18; 10:14-21; 11:2-10; 14:8-10; 15:9-17:10; 18:10-22; 24:13-25:1; 31:2-6; 31:18-32:6; 32:16-19; 36:11-37:9; 38:15-39:1; 40:2-9; 40:19-41:4; 80:8-81:3; 81:11-18; 82:9-83:20; 105:17-20; 142:6-10; 144:15-145:10; 155:17-156:4; 156:16-18; 168:5-169:7; 171:12-14; 179:20-181:13; 185:19-186:6; 186:21-187:5; 187:22-189:1; 190:10-15; 191:5-192:4; 193:4-20; 201:18-202:2
	<b>Cryovac Counter-Designations</b>	11:11-14; 12:14-19; 14:11-16; 33:8-13; 34:4-6; 34:8-15; 81:4-10; 81:19-20; 82:1-7; 83:22-84:9; 84:21-85:13; 86:7-16; 86:18-87:2; 87:5-14; 87:16-88:1; 92:7-12; 98:22-99:10; 99:13-15; 99:17-19; 99:22-100:4; 100:6-8; 100:11-22; 149:21-150:7; 154:8-9; 154:12; 154:14-155:5; 156:5-7; 156:9-14; 160:4-6; 160:8-10; 162:13-18; 163:1-8; 164:7-11; 164:16-22; 167:13-20; 167:22-168:3; 186:9-20; 189:5-15; 193:21-194:2; 194:4-13; 195:22-196:5; 196:7-12; 196:15-197:8; 197:11; 197:13-17; 203:18-204:13; 208:2-16; 225:1-226:2; 228:15-229:19; 231:6-21; 232:13-234:2; 235:1-4; 236:8-237:17; 238:12-239:7

\*Cryovac only counter-designates this testimony if its objections to Pechiney's designations are overruled.



<b>Anthony York</b>  8/9/2005	Pechiney Designations	9:8-22; 11:22-12:9; 24:9-17; 25:11-14; 26:8-27:5; 27:13-29:15; 30:5-31:8; 36:21-38:12; 38:18-21; 41:3-17; 42:10-43:10; 46:13-47:10; 51:11-53:11; 70:5-9; 72:4-14; 74:20-75:1; 75:18-77:22; 82:8-83:7; 87:18-92:3; 121:13-122:10; 123:1-123:15; 153:1-159:22; 166:5-14; 196:3-15; 200:4-201:1; 225:1-226:1; 232:22-233:14; 235:5-8; 235:20-236:1; 236:12-237:11; 237:19-238:19; 239:4-7; 243:15-245:2; 278:2-5; 278:13-22; 281:5-11; 284:19-288:1; 289:7-17; 291:4-292:2; 294:2-297:8; 297:19-298:1; 299:1-300:8; 304:21-306:4; 307:2-308:15; 308:22-309:22; 316:1-319:11; 320:21-323:2; 323:10-16
	Cryovac Counter- Designations	16:19-22; 21:1-22:6; 22:16-23:5; 23:11-15; 23:19-22; 24:18-25:8; 27:6-12; 29:16-30:4; 38:22-39:3; 53:21-54:9; 54:19-55:3; 70:10-13; 71:4-8; 71:18-72:3; 74:7-11; 78:1-11; 85:14-86:12; 86:16-87:17; 92:7-96:16; 97:2-101:1; 103:20-106:4; 109:7-111:22; 120:18-121:12; 122:22; 123:16-124:1; 124:4-12; 125:2-9; 125:12-18; 167:21-168:5; 168:11-169:16; 170:3-8; 173:19-174:1; 174:4-175:14; 175:21-176:7; 186:17-188:16; 188:18-189:7; 196:16-17; 197:2-10; 198:12-199:5; 203:1-8; 206:13-207:12; 207:14; 207:16-17; 207:22-208:1; 208:3-208:22; 209:6-16; 227:21-228:8; 228:11-228:16; 228:20-230:2; 242:7-15*; 292:6-17*; 306:6-22; 311:11-315:16; 320:4-16

\*Cryovac only counter-designates this testimony if its objections to Pechiney's designations are overruled.



## **EXHIBIT 10**

**Exhibit 10: Crvovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**Kelly Ray Ahlgren**

**August 10, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
87:8-88:20	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
109:6-20	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
131:6-20	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
185:6-186:10	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>****Karl Deily****August 19, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
10:9-11:22	FRE 402 FRE 403
33:2-17	FRE 402 FRE 403
36:13-:52:12	FRE 402 FRE 403
72:5-74:19	FRE 402 FRE 403
78:17-82:20	FRE 402 FRE 403
86:20-93:21	FRE 402 FRE 403
94:13-98:19	FRE 402 FRE 403
100:3-106:18	FRE 402 FRE 403
116:7-22	FRE 402 FRE 403
117:1-119:6	FRE 402 FRE 403 FRE 602
127:4-128:10	FRE 402 FRE 403
145:11-13	FRE 402 FRE 403
148:19-22	FRE 402 FRE 403
159:5-10	FRE 402 FRE 403
165:5-169:9	FRE 402 FRE 403
173:22	FRE 402 FRE 403

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>****Karl Deily****August 19, 2005 (Continued)**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
182:10-12	FRE 402
	FRE 403
183:13-14	FRE 402
	FRE 403
185:15-186:3	FRE 402
	FRE 403
186:12-13	FRE 402
	FRE 403
236:4	FRE 402
	FRE 403
238:11	FRE 402
	FRE 403
239:20	FRE 402
	FRE 403
244:10-246:6	FRE 402
	FRE 403
251:3	FRE 402
	FRE 403
253:3-255:2	FRE 402
	FRE 403
256:2-17	FRE 402
	FRE 403
257:3-4	FRE 402
	FRE 403
258:2-3	FRE 402
	FRE 403
258:21	FRE 402
	FRE 403
259:15-16	FRE 402
	FRE 403
261:1-3	FRE 402
	FRE 403
286:2	FRE 402
	FRE 403

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

Karl Deily

August 19, 2005 (Continued)

<u>Designation</u>	<u>Objections</u>
291:11	FRE 402 FRE 403
291:22	FRE 402 FRE 403
292:13-14	FRE 402 FRE 403
292:22-293:1	FRE 402 FRE 403
297:10-11	FRE 402 FRE 403
302:12-13	FRE 402 FRE 403
303:9-10	FRE 402 FRE 403
305:6	FRE 402 FRE 403
305:20-307:13	FRE 402 FRE 403

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**Ennis M. Fant**

**July 19, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
55:21–56:9	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
89:22–92:5	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
102:22–103:7	FRE 701 (improper lay opinion)
127:20-128:22	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) FRE 602 (lack of personal knowledge)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

Steven L. Fuller

August 18, 2005

<b><u>Designation</u></b>	<b><u>Objections</u></b>
84:10-13	FRE 602 (lack of personal knowledge)
84:21-85:3	FRE 602 (lack of personal knowledge)
85:9-22	FRE 602 (lack of personal knowledge)
91:14-21	FRE 602 (lack of personal knowledge)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**Jeffrey Gardner**

**August 2, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
11:12-12:4	FRE 402 FRE 403
23:1-3	FRE 402
26:1-10	FRE 402
44:2-3	FRE 402 FRE 403
45:4	FRE 402 FRE 403
45:22	FRE 402 FRE 403
48:21	FRE 402 FRE 403
49:18	FRE 402 FRE 403
52:14	FRE 402 FRE 403
53:19	FRE 402 FRE 403
57:21	FRE 402 FRE 403
58:12	FRE 402 FRE 403
59:22-60:1	FRE 402 FRE 403
64:3	FRE 402 FRE 403
95:2-11	FRE 402 FRE 403 FRE 602 FRE 801
96:8-14	FRE 701 FRE 801

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.



**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**Jeffrey Gardner**

**August 2, 2005 (Continued)**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
100:13-102:10	FRE 402 FRE 403 FRE 701
129:1-8	FRE 402 FRE 602
129:9-12	FRE 402 FRE 403
129:17-130:18	FRE 402
130:22-131:17	FRE 402 FRE 602
131:18-132:11	FRE 402
134:18-144:5	FRE 402 FRE 403
171:12-173:2	FRE 402 FRE 403
177:13-179:4	FRE 402 FRE 403 FRE 602 FRE 701
179:5	FRE 402 FRE 403
179:6-180:19	FRE 402 FRE 403 FRE 602 FRE 701
180:20-183:17	FRE 402 FRE 403
184:15-189:11	FRE 402 FRE 403
189:12-191:10	FRE 402 FRE 403 FRE 602

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>****Jeffrey Gardner****August 2, 2005 (Continued)**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
191:11-20	FRE 402 FRE 403
191:21-193:13	FRE 402 FRE 403 FRE 602
193:14-194:9	FRE 402 FRE 403
202:1-204:1	FRE 402 FRE 403
209:6-212:11	FRE 402 FRE 403 FRE 602
212:15-216:8	FRE 402 FRE 403 FRE 602
216:9-22	FRE 402 FRE 403 FRE 602 FRE 801
217:1-3	FRE 402 FRE 403 FRE 802
217:4-218:16	FRE 402 FRE 403 FRE 602
218:17-220:5	FRE 402 FRE 403
220:11-221:21	FRE 402 FRE 403
226:14-227:6	FRE 402
257:14-259:11	FRE 402 FRE 403
258:16	FRE 402 FRE 403

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>****Steven B. Garland****August 9, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
26:8-27:18	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
38:21-40:13	FRE 402 (lack of relevance) FRE 602 (lack of personal knowledge)
53:6-20	FRE 402 (lack of relevance) FRE 602 (lack of personal knowledge)
100:6-10	FRE 602 (lack of personal knowledge)
101:18-102:15	FRE 402 (lack of relevance) FRE 602 (lack of personal knowledge)
110:11-16	FRE 602 (lack of personal knowledge)
111:6-12	FRE 602 (lack of personal knowledge)
113:7-8	FRE 602 (lack of personal knowledge)
114:12-115:10	FRE 602 (lack of personal knowledge)
133:7-21	FRE 602 (lack of personal knowledge)
136:4-137:5	FRE 602 (lack of personal knowledge)
150:9-152:12	FRE 602 (lack of personal knowledge)
155:1-21	FRE 602 (lack of personal knowledge)
162:3-5	FRE 602 (lack of personal knowledge)
162:10-18	FRE 602 (lack of personal knowledge)
163:19-168:15	FRE 402 (lack of relevance)
169:11-15	FRE 602 (lack of personal knowledge)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

Steve James

September 7, 2005

<u>Designation</u>	<u>Objections</u>
12:2	FRE 402 FRE 403
14:13-16	FRE 402 FRE 403
15:10-16	FRE 402 FRE 403 FRE 701
16:4-8	FRE 402 FRE 403 FRE 701
16:9	FRE 402 FRE 403
16:10	FRE 402 FRE 403 FRE 701
21:1-25	FRE 402 FRE 403 FRE 801
22:1-13	FRE 402 FRE 403
26:13-24	FRE 402 FRE 403
27:14	FRE 402 FRE 403
28:1 – 29:19	FRE 402 FRE 403 FRE 602 FRE 701 FRE 801

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

Steve James

September 7, 2005 (Continued)

<u>Designation</u>	<u>Objections</u>
30:9-11	FRE 402
	FRE 403
30:12-15	FRE 402
	FRE 403
	FRE 602
	FRE 701
31:11	FRE 402
	FRE 403
31:20-23	FRE 402
	FRE 403
	FRE 602
	FRE 701
31:24-25	FRE 402
	FRE 403
32:1	FRE 402
	FRE 403
	FRE 602
	FRE 701
48:20 – 49:12	FRE 602
51:7-9	FRE 402
	FRE 403

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>****Tommy Kay****August 16, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
39:9-16	FRE 701 (improper lay opinion)
40:12-41:21	FRE 701 (improper lay opinion)
151:2-21	FRE 402 (lack of relevance) FRE 602 (lack of personal knowledge) FRE 701 (improper lay opinion)
153:14-18	FRE 402 (lack of relevance) FRE 602 (lack of personal knowledge) FRE 701 (improper lay opinion)
157:8-13	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
158:13-159:2	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
161:14-162:1	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
163:8-10	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
167:6-21	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
173:7-174:4	FRE 602 (lack of personal knowledge)
174:18-176:15	FRE 602 (lack of personal knowledge) FRE 701 (improper lay opinion)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

Tommy Kay

August 16, 2005 (continued)

<u>Designation</u>	<u>Objections</u>
176:23-177:5	FRE 402 (lack of relevance)
189:2-190:12	FRE 602 (lack of personal knowledge)
198:22-25	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
201:11-14	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) FRE 701 (improper lay opinion) Subject to motion-in-limine

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>****Robert M. Kimmel****July 13, 2005**

Cryovac objects to the use of Dr. Kimmel's deposition for any purpose other than contradicting or impeaching Dr. Kimmel pursuant to Fed. R. Civ. P. 32(a)(1). Dr. Kimmel is not an officer, director, managing agent or 30(b)(6) witness and thus his deposition testimony is not admissible pursuant to Fed. R. Civ. P. 32(a)(2). Nor is his testimony permitted pursuant to any of the subparagraphs of Fed. R. Civ. P. 32(a)(3). In addition, Cryovac objects to Pechiney's specific designations from Dr. Kimmel's transcript as follows:

<b><u>Designation</u></b>	<b><u>Objections</u></b>
25:3-14	FRE 403 (jury confusion) (subject to motion-in-limine)
33:12-22	FRE 403 (jury confusion) (subject to motion-in-limine)
57:11-18	FRE 403 (jury confusion) (subject to motion-in-limine)
61:14-63:17	FRE 403 (jury confusion) (subject to motion-in-limine)
72:8-74:1	FRE 403 (jury confusion) (subject to motion-in-limine)
75:2-14	FRE 403 (jury confusion) (subject to motion-in-limine)
81:8-20	FRE 403 (jury confusion) (subject to motion-in-limine)
161:6-22	FRE 403 (jury confusion) (subject to motion-in-limine)
258:8-12	FRE 403 (jury confusion) (subject to motion-in-limine)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.



**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**James Mize**

**August 17, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
30:4-5	FRE 402 FRE 403
63:17-18	FRE 402 FRE 403
64:5-6	FRE 402 FRE 403
64:14-15	FRE 402 FRE 403
65:8-9	FRE 402 FRE 403
66:3-5	FRE 402 FRE 403
66:17-18	FRE 402 FRE 403
67:6-7	FRE 402 FRE 403
67:15-16	FRE 402 FRE 403
69:9-10	FRE 402 FRE 403
75:12	FRE 402 FRE 403
94:16-94:21	FRE 602

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**James Mize**

**August 17, 2005 (Continued)**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
94:22	FRE 402 FRE 403
95:1-3	FRE 602
95:5-7	FRE 602
95:8-9	FRE 402 FRE 403
95:10-16	FRE 602
96:5	FRE 402 FRE 403
100:19	FRE 402 FRE 403
101:3	FRE 402 FRE 403
101:8-22	FRE 402 FRE 403 Outside Scope of 30(b)(6)
104:15-16	FRE 402 FRE 403
105:14-19	FRE 402 FRE 403
106:15-22	FRE 402 FRE 403

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

James Mize

August 17, 2005 (Continued)

<u>Designation</u>	<u>Objections</u>
107:7-13	FRE 402 FRE 403
108:4-8	Outside Scope of 30(b)(6)
108:9-11	FRE 402 FRE 403
108:13-14	Outside Scope of 30(b)(6)
109:12-16	FRE 402 FRE 403
111:3-4	FRE 402 FRE 403
111:18-112:1	FRE 402 FRE 403
139:10-12	FRE 402 FRE 403
139:21	FRE 402 FRE 403
154:2-157:1	FRE 402 602 802
157:2-:165:8	FRE 402 FRE 403
165:9-166:7	FRE 802

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>****James Mize****August 17, 2005 (Continued)**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
169:3-185:13	FRE 402 FRE 403
189:17-211:21	FRE 402 FRE 403
212:8-22	FRE 402 FRE 403
217:1-220:2	FRE 402 FRE 403
220:4-222:17	FRE 402 FRE 403 FRE 602
222:19-228:2	FRE 402 FRE 403
231:11-14	FRE 402 FRE 403 FRE 602
232:20-234:14	FRE 402 FRE 403 FRE 602
234:22-236:12	FRE 402 FRE 403 FRE 602
238:13-243:6	FRE 402 FRE 403 FRE 602

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**Stuart Prosser**

**September 14, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
10:19-11:7	FRE 402 FRE 403
14:17-15:6	FRE 402 FRE 403
18:8-20:10	FRE 402 FRE 403
22:9-23:24	FRE 402 FRE 403
28:17-30:24	FRE 402 FRE 403
38:13-40:7	FRE 402 FRE 403
41:1-44:19	FRE 402 FRE 403
46:4-48:2	FRE 402 FRE 403

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>****Mark Quatt****August 12, 2005**

Cryovac objects to the use of Mr. Quatt's deposition for any purpose other than contradicting or impeaching Mr. Quatt pursuant to Fed. R. Civ. P. 32(a)(1). Mr. Quatt is not an officer, director, managing agent or 30(b)(6) witness and thus his deposition testimony is not admissible pursuant to Fed. R. Civ. P. 32(a)(2). Nor is his testimony permitted pursuant to any of the subparagraphs of Fed. R. Civ. P. 32(a)(3). In addition, Cryovac objects to Pechiney's specific designations from Mr. Quatt's transcript as follows:

<b><u>Designation</u></b>	<b><u>Objections</u></b>
15:12-16	FRE 402 (lack of relevance)
15:18-16:6	FRE 402 (lack of relevance)
17:18-18:2	FRE 402 (lack of relevance)
46:17-19	FRE 403 (unfair prejudice) FRE 603 (unsworn)
105:7-108:6	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
115:17-22	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
116:4-117:6	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
124:10-16	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
126:2-127:16	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

Mark Quatt

August 12, 2005 (continued)

<b><u>Designation</u></b>	<b><u>Objections</u></b>
128:14-129:8	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
150:11-151:4	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
163:15-164:16	FRE 402 (lack of relevance)
202:7-12	FRE 402 (lack of relevance)
206:11-207:5	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
210:10-212:1	FRE 602 (lack of personal knowledge) FRE 701 (improper lay opinion)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>****Gautam P. Shah****August 11, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
14:18-16:20	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
17:8 - 19:15	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
27:2-28:5	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
151:10-16	FRE 402 (lack of relevance) FRE 403 (unfair prejudice) FRE 603 (unsworn attorney colloquy)
171:3-21	FRE 701 (improper lay opinion)
172:3-8	FRE 402 (lack of relevance) FRE 403 (jury confusion)
173:2-11	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
177:3-9	FRE 403 (jury confusion)
178:13-179:11	FRE 403 (jury confusion)
194:2-11	FRE 402 (lack of relevance) FRE 403 (jury confusion) Subject to motion-in-limine

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.



**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**Gautam P. Shah**

**August 11, 2005 (Continued)**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
194:22–195:13	FRE 402 (lack of relevance) FRE 403 (jury confusion) Subject to motion-in-limine
197:13–199:2	FRE 402 (lack of relevance) FRE 403 (jury confusion) Subject to motion-in-limine
201:3–14	FRE 402 (lack of relevance) FRE 403 (jury confusion) Subject to motion-in-limine
245:15–252:15	FRE 602 (lack of personal knowledge)
254:4–255:14	FRE 402 (lack of relevance) FRE 403 (jury confusion)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**Gautam P. Shah**

**Rule 30(b)(6)**

**August 11, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
20:4–12	FRE 402 (lack of relevance)
20:14–21:21	FRE 403 (unfair prejudice; jury confusion)
23:19–27:9	FRE 403 (unfair prejudice; jury confusion) FRE 603 (unsworn attorney colloquy)
39:6–40:15	FRE 402 (lack of relevance)
49:15–50:2	FRE 402 (lack of relevance)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**F. David Stringer**

**August 19, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
19:25–20:9	FRE 402 (lack of relevance)
80:13–81:1	FRE 602 (lack of personal knowledge)
114:14–115:1	FRE 602 (lack of personal knowledge)
124:25–125:23	FRE 402 (lack of relevance) FRE 403 (jury confusion; waste of time) Subject to motion-in-limine
145:20–146:8	FRE 701 (improper lay opinion) FRE 403 (jury confusion; unfair prejudice)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**Terry Wilkerson**

**August 24, 2005**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
10:5-8	FRE 402 FRE 403
10:13-19	FRE 402 FRE 403
14:7-19	FRE 602
18:14-19:2	FRE 402 FRE 403 FRE 602
20:25-23:3	FRE 602
23:13-25 32:23	FRE 602 FRE 402 FRE 403
32:25-33:8	FRE 402 FRE 403
36:25-39:4	FRE 402
40:8-10	FRE 402
42:21-43:16	FRE 402
47:15-18	FRE 402 FRE 403
50:20-51:11	FRE 402 FRE 403
57:11-18	FRE 402 FRE 403

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

Terry Wilkerson

August 24, 2005 (Continued)

<u>Designation</u>	<u>Objections</u>
62:11	FRE 402 FRE 403
62:17-19	FRE 402 FRE 403
63:4-7	FRE 402 FRE 403
71:10-14	FRE 402 FRE 403
77:18	FRE 402 FRE 403
80:1-15	FRE 402 FRE 403
80:23	FRE 402 FRE 403
115:24-116:1	FRE 402 FRE 403
118:23-119:4	FRE 402 FRE 403
122:10-19	FRE 402 FRE 403
139:13	FRE 402 FRE 403
141:18-23	FRE 402 FRE 403
142:2-3	FRE 402 FRE 403
143:7-8	FRE 402 FRE 403
145:6-7	FRE 402 FRE 403
145:14-16	FRE 402 FRE 403

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

Terry Wilkerson

August 24, 2005 (Continued)

<u>Designation</u>	<u>Objections</u>
154:5-24	FRE 402 FRE 403
157:10-11	FRE 402 FRE 403
159:8-11	FRE 402 FRE 403

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>****Garth L. Wilkes****July 20, 2005**

Cryovac objects to the use of Dr. Wilkes' deposition for any purpose other than contradicting or impeaching Dr. Wilkes pursuant to Fed. R. Civ. P. 32(a)(1). Dr. Wilkes is not an officer, director, managing agent or 30(b)(6) witness and thus his deposition testimony is not admissible pursuant to Fed. R. Civ. P. 32(a)(2). Nor is his testimony permitted pursuant to any of the subparagraphs of Fed. R. Civ. P. 32(a)(3). In addition, Cryovac objects to Pechiney's specific designations from Dr. Wilkes' transcript as follows:

<b><u>Designation</u></b>	<b><u>Objections</u></b>
175:15-176:14	Form objections on record FRE 403 (jury confusion)
220:4-222:18	FRE 403 (jury confusion) Subject to motion-in-limine
239:5-12	FRE 403 (jury confusion) Subject to motion-in-limine
240:5-15	FRE 403 (jury confusion) Subject to motion-in-limine
332:4-333:11	Form objection on record FRE 402 (lack of relevance) FRE 403 (jury confusion)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

Jay Wilson

November 3, 2005

<b><u>Designation</u></b>	<b><u>Objections</u></b>
13:8	FRE 402 FRE 403
20:19-20	FRE 402 FRE 403
21:4-9	FRE 402 FRE 403 Outside scope of 30(b)(6)
21:10-17	FRE 402 FRE 403
21:18-22:3	FRE 402 FRE 403 Outside scope of 30(b)(6)
22:5-10	FRE 402 FRE 403 Outside scope of 30(b)(6)
22:11-14	FRE 402 FRE 403
22:15-17	FRE 402 FRE 403 Outside Scope of 30(b)(6)
23:11	FRE 402 FRE 403
23:8-10; 23:12-18	FRE 402 FRE 403 Outside Scope of 30(b)(6)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.



**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

Jay Wilson

November 3, 2005 (Continued)

<u>Designation</u>	<u>Objections</u>
23:20-24:5	FRE 402 FRE 403 Outside Scope of 30(b)(6)
24:6-13	FRE 402 FRE 403 Outside Scope of 30(b)(6)
24:14-25:5	FRE 402 FRE 403 Outside Scope of 30(b)(6)
25:9-17	FRE 402 FRE 403
31:11-39:19	FRE 402 FRE 403
50:5-51:20; 51:22-52:2 52:3-52:17	FRE 402 FRE 403
67:9-21	FRE 402 FRE 403 FRE 602
69:9-70:5	FRE 402 FRE 403
73:19-78:8	FRE 402 FRE 403
83:5-84:13	FRE 402 FRE 403

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

**Jay Wilson**

**November 3, 2005 (Continued)**

<b><u>Designation</u></b>	<b><u>Objections</u></b>
86:2-87:16	FRE 402 FRE 403
88:13-93:14	FRE 402 FRE 403
98:5-103:1	FRE 402 FRE 403
103:21-104:5	FRE 402 FRE 403
105:7-107:21	FRE 402 FRE 403
108:8-110:13	FRE 402 FRE 403
113:10-114:6	FRE 402 FRE 403 FRE 602

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

George Wofford

August 12, 2005

<b><u>Designation</u></b>	<b><u>Objections</u></b>
80:8-81:3	Subject to motion-in-limine FRE 402 (lack of relevance) FRE 403 (jury confusion)
168:5-169:6	FRE 602 (lack of personal knowledge)
179:20-181:13	FRE 402 (lack of relevance)
185:19-186:6	FRE 402 (lack of relevance)
186:21-187:5	FRE 402 (lack of relevance)
187:22-189:1	FRE 402 (lack of relevance)
190:10-15	FRE 402 (lack of relevance)
191:5-192:4	FRE 402 (lack of relevance)
193:4-20	FRE 402 (lack of relevance)
201:18-202:2	FRE 402 (lack of relevance)

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.

**Cryovac's Objections to Pechiney's Deposition Designations<sup>1</sup>**

Anthony York

August 9, 2005

<b><u>Designation</u></b>	<b><u>Objections</u></b>
28:7-8	FRE 402 FRE 403
52:11-53:11	FRE 402 FRE 403
200:4-17	FRE 402 FRE 403
200:18-201:1	FRE 402 FRE 403 FRE 802
238:5-19	FRE 802
239:4-7	FRE 802
243:15-245:2	FRE 802
278:2-5	FRE 402
278:13-22	FRE 402
281:5-11	FRE 402
284:19-22	FRE 402
285:1-6	FRE 402 FRE 802
286:5-288:1	FRE 402
289:7-17	FRE 402
291:4-292:2	FRE 402
294:2-297:8	FRE 402
297:19-298:1	FRE 402
318:13-319:11	FRE 402

<sup>1</sup> In addition to the specific objections noted herein, Cryovac generally objects to Pechiney's inclusion of attorney colloquy, objections, and unanswered questions in their designations. Such designations are inadmissible under FRE 603.